$15m cap raise Fresh Equities at 24c, page-524

Thanks Uboy. Very helpful. The platform drug potential is exciting, but I understand ANP has been flogging ATL1102 for 20 years (15 in MS) and the DMD application is the only one that's struck some success in the eyes of investors. Realise it's probably the Pinto-Mariz (?) study in 2015 that was the catalyst for expanding the anti-inflam applications of ATL1102 - hence the pivot from MS to DMD. Would like to understand the commercial protections ANP has though (ie patents) - just to rest easier - as it's an important input in the future earnings calculation. Ionis license complicates things somewhat. Someone should know as there is substantial money at risk from many posters.